Recently, a large study including 4,147 pre- and post-menopausal women with invasive BC from the Nurses' Health Study cohorts showed that AR expression, independent of clinicopathological characteristics, was related to the improvement of BC-specific survival in ER+ BC patients in the first 5–10 years post-diagnosis (43). This evidence concerns the gene ESR1 and breast cancer.